AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7924365 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications containing glucose
Number of subjects: 30
Study 7924365 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose
Number of subjects: 30
Study 3241259 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 0
Study 3241259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1644987 — intervention group
Group type: EXPERIMENTAL
Intervention: Early partial sleep deprivation (PSD)
Number of subjects: 30
Study 1644987 — intervention group
Group type: EXPERIMENTAL
Intervention: Late partial sleep deprivation (PSD)
Number of subjects: 30
Study 1644987 — intervention group
Group type: COMPARATOR
Intervention: Total sleep time held constant (168 +/- 46 min in early sleep, 173 +/- 28 min in late sleep)
Number of subjects: 30
Study 333603 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cephalosporin
Number of subjects: 80
Study 333603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31582622 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C lowering drug therapy (primarily statins)
Number of subjects: 104
Study 31582622 — intervention group
Group type: COMPARATOR
Intervention: No LDL-C lowering drug therapy
Number of subjects: 104
Study 31730454 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological morbidity assessment using the General Health Questionnaire (GHQ)-12
Number of subjects: 751
Study 31730454 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with psychological morbidity
Number of subjects: 751
Study 27875094 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS
Number of subjects: 149
Study 27875094 — intervention group
Group type: COMPARATOR
Intervention: Conventional pathway
Number of subjects: 149
Study 26094838 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg with breakfast and lunch
Number of subjects: 23
Study 26094838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 22999292 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine plus risperidone
Number of subjects: 0
Study 22999292 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus risperidone
Number of subjects: 0
Study 21338973 — intervention group
Group type: EXPERIMENTAL
Intervention: PowerPoint presentation with illustrations on laparoscopic cholecystectomy
Number of subjects: 50
Study 21338973 — intervention group
Group type: COMPARATOR
Intervention: Standard explanation of surgical risks, complications, and benefits
Number of subjects: 50
Study 19696138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerecyte coils
Number of subjects: 128
Study 19696138 — intervention group
Group type: COMPARATOR
Intervention: Bare platinum coils
Number of subjects: 128
Study 17373220 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandio restorative system
Number of subjects: 40
Study 17373220 — intervention group
Group type: COMPARATOR
Intervention: Transbond adhesive system
Number of subjects: 40
Study 14648073 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg calcium carbonate for 6 weeks)
Number of subjects: 27
Study 14648073 — intervention group
Group type: COMPARATOR
Intervention: Control (no calcium supplementation)
Number of subjects: 27
Study 11558809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular compression (performed three times a day with a specific pattern of pressure application)
Number of subjects: 29
Study 11558809 — intervention group
Group type: COMPARATOR
Intervention: Cheekbone compression (control group, applied pressure to the zygomatic arch with the same frequency)
Number of subjects: 29
Study 9645782 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured case-based discussions
Number of subjects: 42
Study 9645782 — intervention group
Group type: COMPARATOR
Intervention: Structured case-based discussions
Number of subjects: 42
Study 7871090 — intervention group
Group type: COMPARATOR
Intervention: alpha-2 adrenoceptor antagonist (high dose)
Number of subjects: 12
Study 3222146 — intervention group
Group type: EXPERIMENTAL
Intervention: (A, B, C) staging system
Number of subjects: 935
Study 3222146 — intervention group
Group type: COMPARATOR
Intervention: Rai's staging system (stage 0)
Number of subjects: 935
Study 3222146 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of (A, B, C) staging system with Rai's staging system
Number of subjects: 935
Study 31617447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery Learning (ML)
Number of subjects: 145
Study 31617447 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Directed Learning (SDL)
Number of subjects: 145
Study 31617447 — intervention group
Group type: EXPERIMENTAL
Intervention: Online learning module (1 week prior) + Face-to-face component (45 minutes)
Number of subjects: 145
Study 31617447 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 145
Study 28978818 — intervention group
Group type: EXPERIMENTAL
Intervention: G1-DES (First-Generation Drug-Eluting Stents)
Number of subjects: 4140
Study 28978818 — intervention group
Group type: EXPERIMENTAL
Intervention: G2-DES (Second-Generation Drug-Eluting Stents)
Number of subjects: 4140
Study 28386781 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-titrating continuous positive airway pressure (CPAP) for up to 1 year
Number of subjects: 225
Study 28386781 — intervention group
Group type: COMPARATOR
Intervention: Usual care and unattended polysomnography at the end of the study
Number of subjects: 225
Study 28386781 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-titrating CPAP
Number of subjects: 225
Study 24858488 — intervention group
Group type: EXPERIMENTAL
Intervention: CON-CT
Number of subjects: 72
Study 24858488 — intervention group
Group type: EXPERIMENTAL
Intervention: HI-CT
Number of subjects: 72
Study 24858488 — intervention group
Group type: COMPARATOR
Intervention: RT-only
Number of subjects: 72
Study 24858488 — intervention group
Group type: COMPARATOR
Intervention: HC
Number of subjects: 72
Study 23539235 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anaesthesia
Number of subjects: 1155
Study 23539235 — intervention group
Group type: COMPARATOR
Intervention: Blinded BIS monitoring (control)
Number of subjects: 1155
Study 23539235 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 1155
Study 22130747 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative stepped care intervention led by lay health counsellors
Number of subjects: 2796
Study 22130747 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 2796
Study 19320897 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure instillation therapy
Number of subjects: 30
Study 19320897 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical debridement with gentamicin polymethylmethacrylate beads and long‐term intravenous antibiotics (Control)
Number of subjects: 30
Study 17081208 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial-based dual-chamber managed ventricular pacing mode (MVP™)
Number of subjects: 1000
Study 17081208 — intervention group
Group type: COMPARATOR
Intervention: VVI 40 pacing
Number of subjects: 1000
Study 17081208 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP™
Number of subjects: 1000
Study 17081208 — intervention group
Group type: COMPARATOR
Intervention: VVI 40
Number of subjects: 1000
Study 15144943 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of carvedilol before discharge
Number of subjects: 363
Study 15144943 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waiting 2 to 4 weeks after hospitalization)
Number of subjects: 363
Study 10813543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with cyclophosphamide (CY) plus G-CSF
Number of subjects: 57
Study 10813543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with CY plus GM-CSF
Number of subjects: 57
Study 10813543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with CY plus GM-CSF (8 days) followed by G-CSF
Number of subjects: 57
Study 10813543 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor mobilization (failed to mobilize >0.4 x 10(6) CD34+ cells/kg)
Number of subjects: 57
Study 10813543 — intervention group
Group type: EXPERIMENTAL
Intervention: Good mobilizers in MM (n=24)
Number of subjects: 57
Study 10813543 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-mobilizers in MM (n=5)
Number of subjects: 57
Study 8925804 — intervention group
Group type: COMPARATOR
Intervention: High-protein meal (80 gm total protein: 4.1 g phenylalanine, 8.2 g leucine, 4.2 g isoleucine, 52 g carbohydrate, 9 g fat)
Number of subjects: 10
Study 8925804 — intervention group
Group type: COMPARATOR
Intervention: High-protein meal
Number of subjects: 10
Study 1516877 — intervention group
Group type: EXPERIMENTAL
Intervention: Remefa S (glycyrrhizinic acid), administered three times a week for 12 months
Number of subjects: 10
Study 1516877 — intervention group
Group type: COMPARATOR
Intervention: Interferon (comparison suggested)
Number of subjects: 10
Study 6148361 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine (300 mg/day)
Number of subjects: 11
Study 6148361 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine (1200 mg/day)
Number of subjects: 11
Study 6148361 — intervention group
Group type: COMPARATOR
Intervention: nothing (control)
Number of subjects: 11
Study 30396629 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair Tai Chi (WCTC)
Number of subjects: 40
Study 30396629 — intervention group
Group type: COMPARATOR
Intervention: Control (normal rehabilitation intervention)
Number of subjects: 40
Study 28407661 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg per day for 12 weeks
Number of subjects: 31
Study 28407661 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1,500 mg per day for 12 weeks
Number of subjects: 31
Study 25806893 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring for the Caregiver Programme (CCP)
Number of subjects: 80
Study 25806893 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study 23261025 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated polyglactin 910 antimicrobial sutures
Number of subjects: 410
Study 23261025 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound closures with polyglactin 910 sutures
Number of subjects: 410
Study 19349077 — intervention group
Group type: EXPERIMENTAL
Intervention: Short DUE (≤8 weeks)
Number of subjects: 141
Study 19349077 — intervention group
Group type: COMPARATOR
Intervention: Long DUE (>8 weeks)
Number of subjects: 141
Study 18316567 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐α‐2b at 5 megaunits/m2
Number of subjects: 11
Study 18316567 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐α‐2b at 10 megaunits/m2
Number of subjects: 11
Study 18316567 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐α‐2b at 5 megaunits/m2 and 10 megaunits/m2
Number of subjects: 11
Study 16025958 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Duzhong Jiangu granule (CDJG)
Number of subjects: 600
Study 16025958 — intervention group
Group type: COMPARATOR
Intervention: Zhuanggu Guanjie pill (ZGP)
Number of subjects: 600
Study 14504154 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA) with bupivacaine (0.25% during operation, 0.125% after operation) and fentanyl (2 microg ml(‐1))
Number of subjects: 38
Study 14504154 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 38
Study 9933260 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically treated patients with IAD and extracranial ICA stenosis
Number of subjects: 0
Study 9933260 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically treated patients with IAD
Number of subjects: 0
Study 9933260 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CE) in patients with IAD
Number of subjects: 0
Study 9933260 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CE) in patients without IAD
Number of subjects: 0
Study 7749445 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lateral rotation therapy
Number of subjects: 69
Study 7749445 — intervention group
Group type: COMPARATOR
Intervention: Stationary bed
Number of subjects: 69
Study 2405324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipelle
Number of subjects: 156
Study 2405324 — intervention group
Group type: COMPARATOR
Intervention: Tis‐u‐trap
Number of subjects: 156
Study 7018048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 50
Study 7018048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31977627 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 80
Study 31977627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 80
Study 31608608 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics prescribed for 44% of the extractions
Number of subjects: 992
Study 31608608 — intervention group
Group type: COMPARATOR
Intervention: No postoperative antibiotics prescribed
Number of subjects: 992
Study 27846058 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational hexavalent vaccine (HV)
Number of subjects: 0
Study 27846058 — intervention group
Group type: COMPARATOR
Intervention: Pentacel (Control)
Number of subjects: 0
Study 26018388 — intervention group
Group type: EXPERIMENTAL
Intervention: ImmunoCard STAT!® CGE test
Number of subjects: 0
Study 26018388 — intervention group
Group type: COMPARATOR
Intervention: rt‐PCR for the detection of E. histolytica / E. dispar DNA
Number of subjects: 0
Study 23603234 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl + 17% EDTA
Number of subjects: 50
Study 23603234 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl + 7% maleic acid
Number of subjects: 50
Study 23603234 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl
Number of subjects: 50
Study 23603234 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water
Number of subjects: 50
Study 23603234 — intervention group
Group type: EXPERIMENTAL
Intervention: QMix
Number of subjects: 50
Study 23603234 — intervention group
Group type: EXPERIMENTAL
Intervention: Maleic acid
Number of subjects: 50
Study 23603234 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA
Number of subjects: 50
Study 21565796 — intervention group
Group type: EXPERIMENTAL
Intervention: D/E + fenofibrate + niacin
Number of subjects: 191
Study 21565796 — intervention group
Group type: EXPERIMENTAL
Intervention: D/E + fenofibrate
Number of subjects: 191
Study 21565796 — intervention group
Group type: EXPERIMENTAL
Intervention: D/E + niacin
Number of subjects: 191
Study 21565796 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 191
Study 19765505 — intervention group
Group type: EXPERIMENTAL
Intervention: Active telephone recruitment into quitline support
Number of subjects: 1562
Study 19765505 — intervention group
Group type: EXPERIMENTAL
Intervention: Active telephone recruitment
Number of subjects: 1562
Study 19765505 — intervention group
Group type: COMPARATOR
Intervention: Participants compared to NSW adult daily smokers
Number of subjects: 1562
Study 17577495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol preoperative, 100 mg IM 1 hour before surgery (group A)
Number of subjects: 60
Study 17577495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol postoperative, 100 mg IM immediately after surgery (group B)
Number of subjects: 60
Study 17577495 — intervention group
Group type: COMPARATOR
Intervention: Saline (group C)
Number of subjects: 60
Study 17577495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol preoperative (group A)
Number of subjects: 60
Study 15143712 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuzhen Yunyu Decoction (NYD)
Number of subjects: 68
Study 15143712 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (Control)
Number of subjects: 68
Study 11740320 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-tetravalent vaccine
Number of subjects: 120
Study 11740320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9973803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide (1 mg/kg/day) in one evening dose
Number of subjects: 40
Study 9973803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide (1 mg/kg/day) divided into two administrations
Number of subjects: 40
Study 9973803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide (2 mg/kg/day) after dosage increase
Number of subjects: 40
Study 9973803 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 8737757 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-propafenone hydrochloride
Number of subjects: 12
Study 8737757 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-propafenone hydrochloride
Number of subjects: 12
Study 2328183 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane in concentrations exceeding 1.2 mmol litre‐1
Number of subjects: 12
Study 6116610 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 8
Study 6116610 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 8
Study 6116610 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 400 mg
Number of subjects: 8
Study 6116610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29445912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pan-fried beef steak (270±20 g)
Number of subjects: 12
Study 29445912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sous-vide beef steak (270±20 g)
Number of subjects: 12
Study 28814143 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3045697
Number of subjects: 51
Study 28814143 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone 25 mg/d
Number of subjects: 51
Study 25810334 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without AF
Number of subjects: 6054
Study 25810334 — intervention group
Group type: COMPARATOR
Intervention: Patients with AF
Number of subjects: 6054
Study 25810334 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of stroke in patients without AF
Number of subjects: 6054
Study 23093232 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal endoscope-assisted ESD
Number of subjects: 51
Study 23093232 — intervention group
Group type: COMPARATOR
Intervention: Routine ESD
Number of subjects: 51
Study 20697028 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight category <2.5 kg
Number of subjects: 27982
Study 20697028 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight category 2.5 to 3.2 kg
Number of subjects: 27982
Study 20697028 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight category 3.2 to 3.9 kg
Number of subjects: 27982
Study 20697028 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight category 3.9 to 4.5 kg
Number of subjects: 27982
Study 20697028 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight category >4.5 kg
Number of subjects: 27982
Study 19808418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 204
Study 19808418 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI plus left linear lesions (LL)
Number of subjects: 204
Study 19808418 — intervention group
Group type: COMPARATOR
Intervention: PVI
Number of subjects: 204
Study 19808418 — intervention group
Group type: COMPARATOR
Intervention: PVI plus LL
Number of subjects: 204
Study 16600933 — intervention group
Group type: EXPERIMENTAL
Intervention: HGI-Lac meal (amylopectin starch plus the fermentable disaccharide lactulose)
Number of subjects: 10
Study 16600933 — intervention group
Group type: EXPERIMENTAL
Intervention: LGI meal (slowly digestible, partly fermentable amylose starch plus cellulose)
Number of subjects: 10
Study 16600933 — intervention group
Group type: COMPARATOR
Intervention: HGI meal (amylopectin starch plus cellulose)
Number of subjects: 10
Study 14584770 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofuroxone-impregnated urinary catheters (Group A)
Number of subjects: 100
Study 14584770 — intervention group
Group type: COMPARATOR
Intervention: Regular silicone-coated Foley catheters (Group B)
Number of subjects: 100
Study 10758949 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 392
Study 10758949 — intervention group
Group type: COMPARATOR
Intervention: Coronary bypass surgery
Number of subjects: 392
Study 8918410 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (50 mg once daily) plus LHRH analogue therapy (goserelin acetate 3.6 mg every 28 days or leuprolide acetate 7.5 mg every 28 days)
Number of subjects: 813
Study 8918410 — intervention group
Group type: COMPARATOR
Intervention: Flutamide (250 mg three times daily) plus LHRH analogue therapy (goserelin acetate 3.6 mg every 28 days or leuprolide acetate 7.5 mg every 28 days)
Number of subjects: 813
Study 8918410 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide plus LHRH‐A
Number of subjects: 813
Study 8918410 — intervention group
Group type: COMPARATOR
Intervention: Flutamide plus LHRH‐A
Number of subjects: 813
Study 2012293 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin
Number of subjects: 100
Study 2012293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6211327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.16 mg by pressurized inhaler; 1 mg nebulized)
Number of subjects: 8
Study 6211327 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (0.8 mg by pressurized inhaler; 5 mg nebulized)
Number of subjects: 8
Study 6211327 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide and Salbutamol
Number of subjects: 8
Study 31666284 — intervention group
Group type: EXPERIMENTAL
Intervention: Website plus telephonic patient navigation (PN) intervention
Number of subjects: 1043
Study 31666284 — intervention group
Group type: COMPARATOR
Intervention: Website intervention
Number of subjects: 1043
Study 30393868 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Pulsed Ultrasound (LIPUS) therapy applied bilaterally for 20 minutes daily for the first 10 days and thereafter at least 3 times per week until complete mandibular advancement was achieved.
Number of subjects: 40
Study 30393868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LIPUS therapy).
Number of subjects: 40